Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sarizotan
- Development stage
- Phase 3
- Lead developer
- Newron Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sarizotan is a small molecule drug developed as a selective 5-HT1A (serotonin) receptor agonist and D2 (dopamine) receptor antagonist. It was originally investigated for its antipsychotic effects and for reducing dyskinesias associated with long-term levodopa treatment in Parkinson's disease. Sarizotan also demonstrated high affinity for D3 and D4 dopamine receptors. The drug was further explored as an oral therapy to treat breathing abnormalities in Rett syndrome, based on its ability to modulate serotonin and dopamine signaling in the brain. Despite promising preclinical results, clinical development for Parkinson's disease was discontinued after Phase III trials failed to meet efficacy endpoints. Later, Newron Pharmaceuticals pursued development of sarizotan for Rett syndrome, receiving orphan drug designation from the FDA.
- Other names
- sarizotan [INN]
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on sarizotan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sarizotan.